RBC Capital maintains Doximity at Outperform, raises price target to $34 from $28

RBC Capital kept Doximity at Outperform, increasing its price target to $34 from $28, suggesting a 2.5% upside from the Nov 5 close of $33.18, according to the firm.

Original reporting
Published Nov 6, 2026, 6:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 6:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RBC Capital maintains Doximity at Outperform, raises price target to $34 from $28 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade may attract new buyers and support the stock price in the near term.

02

Market read

Analyst target raise provides a fresh catalyst for Doximity, offering a modest trading opportunity.

03

What to watch

Potential headwinds from regulatory scrutiny of digital health platforms.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

RBC Capital issued a new price target for Doximity, reflecting optimism on its growth prospects.

Market effects

May lift other health‑tech stocks as analysts reassess sector valuations.

Limited to US markets, primarily affecting Nasdaq health‑tech listings.

Low global impact beyond US investor community.

Counterpoint

Target raise could be premature if recent earnings miss expectations.

Key entities

  • RBC Capital

    Equity research firm that issued the price target upgrade.

  • Doximity

    US‑listed health‑tech platform (ticker DOX).

Related articles

Med

Doximity: 3 Key Takeaways for Long-Term Investors

Doximity updated its full-year revenue guidance to $678M-$683M, citing steady demand and pricing discipline. The company highlights operating efficiency and AI investments as key drivers. According to CFO Matthew Sonefeldt, these factors support continued growth amid technological shifts.

$DOCSMedAI 8/10

DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression

Doximity reported Q3 CY2026 revenue of $174.5M, beating estimates by 2%, with adjusted EPS in line. Adjusted EBITDA exceeded expectations by 9.1%, but operating margin fell to 25.2% from 37.8% YoY. The company raised full-year revenue guidance to $680.5M and maintained EBITDA guidance at $321M. AI product adoption surged, with 16 of the top 20 pharma companies using AI Search. New health system clients and partnerships were added, driving growth.

$DOCSMedAI 8/10

Doximity Q2 Earnings Call Highlights

Doximity (DOCS) reported Q2 earnings, raising fiscal 2027 revenue guidance to $678M-$683M. AI Search revenue is expected to ramp gradually. Health system clients grew to 190, including 10 of the top 20 hospitals. Non-GAAP EPS was $0.36, with $713M in cash. Management discussed AI monetization and adoption challenges.

$DOCSMedAI 8/10

Doximity Earnings Call Highlights AI Growth and Guidance

Doximity (DOCS) reported Q2 revenue of $175M (+4% YoY), beating expectations. Adjusted EBITDA was $89M (51% margin), exceeding guidance. AI initiatives drove growth, with expanded health-system adoption and improved AI economics. Revenue guidance raised to $678M-$683M for 2027. Challenges include modest growth, margin pressure, and AI-search return uncertainty.